HC Wainwright Brokers Lower Earnings Estimates for TYRA

Key Points

• HC Wainwright lowered its EPS forecasts for Tyra Biosciences, projecting a Q3 2026 loss of $0.76 per share versus $0.70 previously. It maintained a Buy rating and a $45 price target.
• Tyra reported a quarterly loss of $0.69 per share, missing the $0.65 consensus estimate. The company remains unprofitable, with full-year 2026 and 2027 losses now estimated at $2.86 and $3.20 per share, respectively.
• Despite the weaker earnings outlook, analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $46.90. Institutional investors own 84.14% of the company.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Tyra Biosciences in a research note issued to investors on Wednesday, August 5th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.76) for the quarter, down from their prior forecast of ($0.70). HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.86) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.80) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.20) EPS.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04).

TYRA has been the topic of a number of other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Friday, July 17th. JonesTrading initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They set a "buy" rating and a $56.00 target price for the company. Wolfe Research assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a "peer perform" rating for the company. Guggenheim began coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They issued a "buy" rating and a $54.00 price target on the stock. Finally, Bank of America upped their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Tyra Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $46.90.

Tyra Biosciences Stock Performance

TYRA stock opened at $26.96 on Friday. The stock has a fifty day moving average of $30.18 and a 200-day moving average of $32.70. Tyra Biosciences has a fifty-two week low of $9.96 and a fifty-two week high of $40.65. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -11.23 and a beta of 0.77.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in shares of Tyra Biosciences during the second quarter valued at about $3,313,000. State of Wyoming bought a new position in shares of Tyra Biosciences in the second quarter valued at approximately $76,000. Walleye Capital LLC bought a new position in shares of Tyra Biosciences in the second quarter valued at approximately $11,112,000. Tema ETFs LLC purchased a new position in Tyra Biosciences during the second quarter valued at approximately $943,000. Finally, Seven Fleet Capital Management LP grew its stake in Tyra Biosciences by 149.6% during the first quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company's stock valued at $7,606,000 after acquiring an additional 119,025 shares in the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences News Summary

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $45 price target for Tyra Biosciences. The target remains well above the stock’s recent trading level, suggesting the firm sees potential upside based on the company’s longer-term pipeline prospects. Tyra Biosciences stock information
• Neutral Sentiment: Analysts continue to broadly support the shares: Tyra carries a consensus “Moderate Buy” recommendation. However, the stock remains unprofitable, with analysts expecting a loss of approximately $2.68 per share for the current fiscal year. Tyra Biosciences receives Moderate Buy consensus
• Negative Sentiment: HC Wainwright reduced its EPS estimates across late 2026 and 2027, including FY2026 to a loss of $2.86 per share from $2.74 and FY2027 to a loss of $3.20 from $3.09. Quarterly estimates were also lowered, indicating expectations for larger losses and potentially higher cash-burn risk. The revisions follow Tyra’s latest quarterly report, in which it posted a $0.69-per-share loss versus the $0.65 consensus estimate. Tyra Biosciences shares gap down after disappointing earnings

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source